Celgene Corporation (CELG) : Mitsubishi Ufj Kokusai Asset Management Ltd. reduced its stake in Celgene Corporation by 2.11% during the most recent quarter end. The investment management company now holds a total of 336,314 shares of Celgene Corporation which is valued at $39,059,508 after selling 7,260 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Celgene Corporation makes up approximately 0.99% of Mitsubishi Ufj Kokusai Asset Management Ltd.’s portfolio.
Other Hedge Funds, Including , Columbus Circle Investors reduced its stake in CELG by selling 51,135 shares or 62.97% in the most recent quarter. The Hedge Fund company now holds 30,071 shares of CELG which is valued at $3,492,446. Celgene Corporation makes up approx 0.03% of Columbus Circle Investors’s portfolio.Zurcher Kantonalbank (zurich Cantonalbank) reduced its stake in CELG by selling 65,119 shares or 13.56% in the most recent quarter. The Hedge Fund company now holds 415,257 shares of CELG which is valued at $48,227,948. Celgene Corporation makes up approx 0.62% of Zurcher Kantonalbank (zurich Cantonalbank)’s portfolio.Redwood Investments boosted its stake in CELG in the latest quarter, The investment management firm added 5,168 additional shares and now holds a total of 146,601 shares of Celgene Corporation which is valued at $15,849,034. Celgene Corporation makes up approx 1.39% of Redwood Investments’s portfolio.Headinvest boosted its stake in CELG in the latest quarter, The investment management firm added 775 additional shares and now holds a total of 21,400 shares of Celgene Corporation which is valued at $2,313,554. Celgene Corporation makes up approx 0.86% of Headinvest’s portfolio.Balasa Dinverno Foltz reduced its stake in CELG by selling 220 shares or 5.31% in the most recent quarter. The Hedge Fund company now holds 3,924 shares of CELG which is valued at $402,995. Celgene Corporation makes up approx 0.07% of Balasa Dinverno Foltz’s portfolio.
Celgene Corporation closed down -1.9 points or -1.64% at $113.63 with 58,53,745 shares getting traded on Monday. Post opening the session at $115.49, the shares hit an intraday low of $112.75 and an intraday high of $115.53 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.